Endothelin receptor antagonists (ERAs) can potentially be used as therapeutic drugs to reduce hypertension caused by small molecule tyrosine kinase inhibitors (TKIs) by Qingjian He, Junling Lin, Chanjuan Mo, Guodong Li, Jianzhong Lu, Qiyin Sun, Lijun Cao, Haojian Gan, Quan Sun, Jiafang Yao, Shengyi Lian, WenJuan Wang

Subjects: Get full text

Tepotinib for the Treatment of Lung Adenocarcinoma Harboring MET Y1003N Point Mutation: A Case Report by Yukihiro Umeda, Satomi Kimura, Junya Kimura, Yoshiaki Imamura, Tamotsu Ishizuka

Subjects: Get full text

A comprehensive overview of selective and novel fibroblast growth factor receptor inhibitors as a potential anticancer modality by Jain Nem Kumar, Tailang Mukul, Thangavel Neelaveni, Makeen Hafiz A., Albratty Mohammed, Najmi Asim, Alhazmi Hassan Ahmad, Zoghebi Khalid, Alagusundaram Muthumanickam, Jain Hemant Kumar, Chandrasekaran Balakumar

Subjects: Get full text

A Bibliometric Analysis of Medullary Thyroid Carcinoma From 2000 to 2022 by TAN Meijuan, YANG Shijie, XU Xiequn

Subjects: Get full text

Advanced breast cancer with pancreatic metastasis responding well to TKIs after ADC failure: Report of a rare case by Huiyun Lv, Wei Liu, Yang Zhang, Chen Song

Subjects: Get full text

Cost-effectiveness of tyrosine kinase inhibitor treatment strategies for chronic myeloid leukemia in South Africa by Rochelle Woudberg, Edina Sinanovic

Subjects: Get full text

Avelumab + axitinib treatment in older patients with advanced renal cell carcinoma in Japan: Subgroup analyses of post‐marketing surveillance data by age by Mototsugu Oya, Taito Ito, Masashi Sato, Makiko Morita, Masahiro Kajita, Norio Nonomura

Subjects: Get full text

Managing novel therapies and concomitant medications in chronic lymphocytic leukemia: key challenges by Sofija Kozarac, Jelena Ivanovic, Marko Mitrovic, Kristina Tomic Vujovic, Isidora Arsenovic, Nada Suvajdzic-Vukovic, Nada Suvajdzic-Vukovic, Andrija Bogdanovic, Andrija Bogdanovic, Ana Vidovic, Ana Vidovic, Milena Todorovic-Balint, Milena Todorovic-Balint, Jelena Bila, Jelena Bila, Mirjana Mitrovic, Mirjana Mitrovic, Danijela Lekovic, Danijela Lekovic, Irena Djunic, Irena Djunic, Marijana Virijevic, Marijana Virijevic, Aleksandar Trivic, Aleksandar Trivic, Jelena Micic, Jelena Micic, Darko Antic, Darko Antic

Subjects: Get full text

Pediatric and adolescent chronic myeloid leukemia: A follow-up study in Western India by Sangita A. Vanik, Dhaval Jetly, Biren Parikh, Karthik Dhandapani, Rukmini Bezbaruah

Subjects: Get full text

Modelling hepatocellular carcinoma microenvironment phenotype to evaluate drug efficacy by Sara Cherradi, Salomé Roux, Marie Dupuy, Séverine Tabone-Eglinger, Edouard Tuaillon, Marianne Ziol, Eric Assenat, Hong Tuan Duong

Subjects: Get full text

Long term efficacy and safety of Lorlatinib in ALK-positive non-small cell lung cancer: A case report by Jialin Qian, Tianqing Chu

Subjects: Get full text

Impact of First- and Second-Generation Tyrosine Kinase Inhibitors on the Development of Graft-Versus-Host Disease in Individuals with Chronic Myeloid Leukemia: A Retrospective Anal... by Ugo Giordano, Agnieszka Piekarska, Witold Prejzner, Lidia Gil, Jan Maciej Zaucha, Joanna Kujawska, Zuzanna Dybko, Krzysztof Dudek, Sebastian Giebel, Jarosław Dybko

Subjects: Get full text

Comparative safety profile of tyrosine kinase inhibitors in NSCLC: a network meta-analysis of hypertension and thrombotic risks by Mingming Tan, Chenwei Pu, Zhenzhen Wang, Chengwei Jin

Subjects: Get full text

Did selective kinase inhibitors change the management of patients with radioiodine-refractory thyroid cancer? by Tommaso Porcelli, Cristina Luongo, Anna Cerbone, Carmine Di Luccio, Mariantonia Nacchio, Maria Angela De Stefano, Martin Schlumberger, Domenico Salvatore

Subjects: Get full text

Gastrointestinal stromal tumors mimicking as gynecological tumors-A case series by Kiran Trivedi, Shabnam Toppo, Apoorwa Sharma, Rohit Kumar Jha, Binit Bharati, Pushpanjali, Tulika Sinha

Subjects: Get full text

Efficiency and safety of HAIC combined with lenvatinib and tislelizumab for advanced hepatocellular carcinoma with high tumor burden: a multicenter propensity score matching analys... by Zhonghua Zhao, Xiongying Jiang, Shiping Wen, Yanzhang Hao

Subjects: Get full text

Emerging targeted therapies in oral oncology: Focus on EGFR inhibition by Vishnu Priya Veeraraghavan, Shikhar Daniel, Arun Kumar Dasari, Kaladhar Reddy Aileni, Chaitra patil, Santosh R. Patil

Subjects: Get full text

Ibrutinib-associated osteonecrosis of the jaw by Annu Singh, Sion Na, Joseph M. Huryn, Cherry L. Estilo, Steven Horwitz, SaeHee K. Yom

Subjects: Get full text

The tyrosine kinase inhibitor lenvatinib is oxidized by rat cytochromes P450 and affects their expression in rat liver by Indra Radek, Jelínková Sandra, Kollárová Katarína, Zahumenská Petra, Dvořák Josef, Dušková Šárka, Dračínská Helena

Subjects: Get full text

Non-small cell lung cancer and the tumor microenvironment: making headway from targeted therapies to advanced immunotherapy by Anna De Lucia, Lucia Mazzotti, Lucia Mazzotti, Anna Gaimari, Anna Gaimari, Matteo Zurlo, Roberta Maltoni, Claudio Cerchione, Sara Bravaccini, Angelo Delmonte, Lucio Crinò, Patricia Borges de Souza, Luigi Pasini, Fabio Nicolini, Fabrizio Bianchi, Manel Juan, Hugo Calderon, Chiara Magnoni, Chiara Magnoni, Luca Gazzola, Luca Gazzola, Paola Ulivi, Massimiliano Mazza

Subjects: Get full text